Evofem raises ~$1.25M net through $2.3M principal convertible notes, warrants, and preferred stock

Evofem Biosciences, Inc.

Raised ~$1.25M net via $2.3M principal senior secured convertible notes, warrants, and Series D Preferred Stock.
Notes convert at $0.05/share, 8% interest, mature in 3 years; warrants exercisable at $0.05 for 46.2M shares.
Series D Preferred Stock has voting rights equal to 1% of common per share, only to approve reverse stock split.
CFO Justin J. File appointed as Secretary; forbearance amended to allow up to $5M additional pari passu debt.
Net proceeds ~$1.25M after expenses; investors paid $650 per $1,000 principal.

item 1.01 item 5.03 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Justin J. File

Secretary

EVFM · Evofem Biosciences, Inc.

Effective: 2022-12-16
Filed: December 21, 2022, 6:59 PM ET

On December 19, 2022 Company appointed Justin J. File as Secretary, effective December 16, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Justin J. File was appointed as Secretary at Evofem Biosciences, Inc..

Action: appointed
Role: Secretary

Exact text from the filing

On December 19, 2022 Company appointed Justin J. File as Secretary, effective December 16, 2022.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Evofem Biosciences, Inc.: 公司提交指定证书创建D系列优先股，构成公司章程修订 (effective 2022-12-16).

Change: charter amendment
Effective: 2022-12-16

Exact text from the filing

On December 16, 2022 the Company filed a certificate of designation to create the Series D Preferred Stock (the “ Certificate of Designation” ) with the Secretary of State, Division of Corporations in Delaware.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Evofem Biosciences, Inc. entered into "SPA" with certain investors valued at $2,307,692 (effective 2022-12-20).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Value: $2,307,692
Effective: 2022-12-20

Exact text from the filing

On December 20, 2022, Evofem Biosciences, Inc., a Delaware corporation (the “ Company” ), entered into a securities purchase agreement (“ SPA” ), with certain investors (the “ Investors ”) providing for the sale and issuance of senior secured convertible notes due in the aggregate original principal amount of $2,307,692 (the “ Notes” ), warrants to purchase an aggregate 46,153,847 shares of common stock (“ Warrants” ) and an aggregate 70 shares of Series D Preferred Stock (the “ Preferred Shares ”) (collectively, the “ Offering” ).

View on SEC.gov

Browse all governance changes →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001618835-22-000211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.